Development and evaluation of nateglinide loaded polycaprolactone nanoparticles

被引:0
作者
Lokhande, Amolkumar [1 ]
Mishra, Satyendra [1 ]
Kulkarni, Ravindra [1 ]
Naik, Jitendra [1 ]
机构
[1] University Institute of Chemical Technology, North Maharashtra University, Jalgaon, Maharashtra
关键词
Drug delivery; Encapsulation efficiency; Nanoparticles; Nateglinide; Polycaprolactone;
D O I
10.2174/1876402907666150624173231
中图分类号
学科分类号
摘要
To observe the effect of Polycaprolactone on Nateglinide release from its nanoparticulate dosage form, the drug and polymer were dissolved in mixture of organic solvent. This solution was homogenized with high speed followed by high pressure homogenizer in surfactant containing aqueous solution. The obtained nanoparticles after solvent evaporation and freeze drying were characterized for particle size, zeta potential, X-ray diffraction, encapsulation efficiency, in-vitro dissolution and drug release kinetics. The developed nanoparticles are in size range of 142.53±6.42 nm to 281.34±3.48 nm. The zeta potential value of most encapsulated formulation batch was +30.2. Nateglinide is crystalline in nature with 86.1% crystallinity but the developed encapsulated nanoparticles showed decrease in crystallinity up to 32.5%. The results showed that the drug released was increased gradually from first hour (7.06±0.24%) to 10th hour (23.13±0.25%) and after that it released in controlled manner up to 24 hours (27.63±1.82%). Polycaprolactone controlled the release of Nateglinide efficiently up to 24 hours. From the release kinetic models it was observed that the dissolution pattern follows Higuchi model. © 2015 Bentham Science Publishers
引用
收藏
页码:43 / 48
页数:5
相关论文
共 17 条
[1]  
Belvis A., Pelone F., Biasco A., Ricciardi W., Volpe M., Can primary care professionals’ adherence to Evidence Based Medicine tools improve quality of care in Type 2 diabetes mellitus? A systematic review, Diabetes Res. Clin. Pract, 85, pp. 119-131, (2009)
[2]  
Tripathi K.D., Essentials of Medical Pharmacology, pp. 167-184, (2003)
[3]  
Standards of Medical Care in Diabetes, Diabetes Care, 31, 1, (2008)
[4]  
Keilson L., Mather S., Walter Y.H., Subramanian S., McLeod J.F., Determination of nateglinide in human plasma by highperformance liquid chromatography with pre-column derivatization using a coumarin-type fluorescent reagent, J. Clin Endocrinol. Metab, 85, (2000)
[5]  
Weaver M.L., Orwig B.A., Rodriguez L.C., Pharmacokinetics and metabolism of nateglinide in humans, Drug Metab. Dispos, 29, pp. 415-421, (2001)
[6]  
Takesada H., Matsuda K., Ohtake R., Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine derivative hypoglycemic agent, Bioorg. Med. Chem, 4, pp. 1771-1781, (1996)
[7]  
Murthy R., Biodegradable polymers, Controlled and Novel Drug Delivery, pp. 27-51, (1997)
[8]  
Sinha V.R., Bansal K., Kaushik R., Kumria R., Trehan A., Poly- _-caprolactone microspheres and nanospheres: An overview, Int. J Pharm, 278, pp. 1-23, (2004)
[9]  
Lokhande A.B., Mishra S., Kulkarni R.D., Naik J.B., Preparation and characterization of repaglinide loaded ethylcellulose nanopaticles by solvent diffusion technique using High pressure homogenizer, J. Pharm. Res, 7, pp. 421-426, (2013)
[10]  
Khairnar G., Mokale M., Naik J., Formulation and development of nateglinide loaded sustained release ethyl cellulose microspheres by O/W solvent emulsification technique, J. Pharm. Invest, 44, pp. 411-422, (2014)